Clevidipine

Clevidipine

Clinical data
Trade names	Cleviprex
AHFS/Drugs.com	Monograph
License data	US DailyMed: Clevidipine
Routes of administration	Intravenous
ATC code	C08CA16 (WHO)
Legal status
Legal status	US: ℞-only EU: Rx-only[1]
Pharmacokinetic data
Bioavailability	100% (used only IV)
Protein binding	>99.5%
Metabolism	Blood and tissue esterases
Elimination half-life	1 minute
Excretion	Urine (63–74%), feces (7–22%)
Identifiers
IUPAC name (RS)-5-O-(Butanoyloxymethyl) 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
CAS Number	167221-71-8 Y
PubChem CID	153994
DrugBank	DB04920
ChemSpider	135722
UNII	19O2GP3B7Q
ChEMBL	ChEMBL1237132
CompTox Dashboard (EPA)	DTXSID6057661
ECHA InfoCard	100.208.117
Chemical and physical data
Formula	C21H23Cl2NO6
Molar mass	456.32 g·mol−1
3D model (JSmol)	Interactive image
Chirality	Racemic mixture
SMILES O=C(OCOC(=O)CCC)\C1=C(\N/C(=C(/C(=O)OC)[C@H]1c2cccc(Cl)c2Cl)C)C

Clevidipine (INN,^[2] trade name Cleviprex) is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. Clevidipine is used IV only and practitioners titrate this drug to lower blood pressure. It has a half-life of approximately one minute. It is rapidly inactivated by esterases.

It was approved by the United States Food and Drug Administration on August 1, 2008.